BEC hydrochloride

Name: BEC hydrochloride
Brand: MedChemExpress
SKU: HY-19548A
Rating: 4.5 (1 reviews)

Cat. No.: HY-19548A Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with K_i of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.

For research use only. We do not sell to patients.

BEC hydrochloride Chemical Structure

CAS No. : 222638-67-7

Size	Price	Stock	Quantity
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 121	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 121	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 370	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 680	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE BEC hydrochloride

•Free Radic Biol Med. 2023 Feb 23;S0891-5849(23)00090-4. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with K_i of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively^[1].

IC₅₀ & Target

Ki: 0.31 μM (BEC hydrochloride, at pH 7.5) and 30 nM (BEC hydrochloride, at pH 9.5)^[1]

In Vitro

The X-ray crystal structure of the arginase-BEC complex has been determined at 2.3 Å resolution from crystals perfectly twinned by hemihedry. The structure of the complex reveals that the boronic acid moiety undergoes nucleophilic attack by metal-bridging hydroxide ion to yield a tetrahedral boronate anion that bridges the binuclear manganese cluster, thereby mimicking the tetrahedral intermediate (and its flanking transition states) in the arginine hydrolysis reaction^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Administration of the arginase inhibitor BEC decreases arginase activity and causes alterations in NO homeostasis, which are reflected by increases in S-nitrosylated and nitrated proteins in the lungs from inflamed mice. BEC enhances perivascular and peribronchiolar lung inflammation, mucus metaplasia, NF-κB DNA binding, and mRNA expression of the NF-κB-driven chemokine genes CCL20 and KC, and leads to further increases in airways hyperresponsiveness^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J wild-type mice, mice deficient in arginase 2 (Arg2^-/-), mice deficient in both arginase 1 and 2 (Arg1^-/-Arg2^-/-), and mice deficient in NOX2 (NOX2^-/-
Dosage:	20 mg/kg.
Administration:	I.V., in 0.9% saline, 1 hour before the injection of LPS.
Result:	BEC robustly reduced VEGF expression in neuroglia (72% reduction) and macrophage/microglia (87% reduction).

Molecular Weight

229.49

Appearance

Solid

Formula

C₅H₁₃BClNO₄S

CAS No.

222638-67-7

SMILES

N[C@@H](CSCCB(O)O)C(O)=O.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (217.87 mM; Need ultrasonic)

DMSO : 50 mg/mL (217.87 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3575 mL	21.7874 mL	43.5749 mL
5 mM	0.8715 mL	4.3575 mL	8.7150 mL
10 mM	0.4357 mL	2.1787 mL	4.3575 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS
Solubility: 140 mg/mL (610.05 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (245 KB) HNMR (194 KB)

Handling Instructions (2659 KB)

References

[1]. Colleluori DM, et al. Classical and slow-binding inhibitors of human type II arginase. Biochemistry. 2001 Aug 7;40(31):9356-62. [Content Brief]

[2]. Kim NN, et al. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry. 2001 Mar 6;40(9):2678-88. [Content Brief]

[3]. Ckless K, et al. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol. 2008 Sep 15;181(6):4255-64. [Content Brief]